Hi @AaronS76. NanoDX will be the first product commercialised by NanoDiagnostics. In fact if you look at the history of Sergei Dryga, CSO for NanoDiagnostics, you get a feel for the enormity of what they are bringing to market. Sergey has been successfully filing patents in this field since the 1990’s, and particularly around this application since around 2008. In other words at least 15 years worth of scientific endeavour from him alone. NanoDiagnostics has the role of commercialising this work. The pivot from TBI to COVID has actually fast tracked development , wth $18m injection in 2020 to help in “expediting” to market.
I can actually understand why Sergey would want a “perfect” product when it goes to market, it represents a life times work. IMO, the market has no idea the level of disruption and value NanoDX will bring to the rapid testing POC market.
SE1 Price at posting:
6.0¢ Sentiment: Buy Disclosure: Held
